Global Immunoglobulin Market Expected to Reach USD 17,501 Million by 2025

The immunoglobulin market accounted for USD 9,851 million in 2017, and is projected to reach USD 17,501 million by 2025, registering a CAGR of 7.5 percent from 2018 to 2025. Immunoglobulin is a blood/plasma product, which is prepared from the serum of multiple of donors, and is used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. Immunoglobulin is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. Prevalence of various antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in immunoglobulin indications, improved production & purification processes, growth in awareness towards antibody deficiency, and rare immune disorders among patient population drive the growth of the immunoglobulin market.

Based on application segment, hypogammaglobulinemia was the largest revenue contributor in 2017 toward market growth and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.

Key findings include:

• Myasthenia Gravis segment is projected to grow at the fastest rate.
• Hypogammaglobulinemia was the highest revenue contributor in 2017 and is expected to continue its dominance.
• North America dominated global immunoglobulins market and is projected to grow at a CAGR of 7.3 percent.
• Saudi Arabia is expected to grow at the fastest rate in the LAMEA region, registering a CAGR of 9.1 percent.
• LAMEA was the fastest growing segment growing at a CAGR of 10.2 percent.

In 2017, North America accounted for maximum contribution to the total revenue generated, followed by Asia-Pacific. The major factors responsible for the growth of the immunoglobulin market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. and the presence of large plasma production facilities. The key companies profiled include Baxter international Inc., CSL Ltd, Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products Inc., Shire (Baxalta), and Bayer Healthcare. – Allied Market Research